Medical Oncology and Tumor Pharmacotherapy

, Volume 8, Issue 4, pp 223–228 | Cite as

Monoclonal antibodies in the management of carcinoma patients

  • Mario Roselli
  • Carlo U. Casciani
  • Fiorella Guadagni
  • Oreste Buonomo
  • Beniamino Iorio
  • Alessandra Diodati
  • Vincenzo Vittorini
  • John W. Greiner
  • David Colcher
  • Jeffrey Schlom


The use of monoclonal antibodies (MAbs) in the clinical management of carcinoma patients is reported in the present review. Among the various MAbs generated, MAb B72.3 (LTIB, National Cancer Institute, U.S.A.) has been extensively used in clinical trials either for antigen identification (TAG-72) in sera, or for tumor localization in carcinoma patients. Serum assay results, in colorectal cancer patients, showed the usefulness of the MAb B72.3 in monitoring the clinical course of the malignant disease. Its specific tumor localization (70% of the biopsy specimens) and the immunoscintigraphy studies, afterin vivo administration, have also been discussed. The positive results obtained, markedly contributed in the development of a new intraoperative methodology termed “radioimmunoguided surgery”.

Key words

Monoclonal antibody B72.3 TAG-72 Radioimmunoguided surgery Colorectal cancer 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Kohler G, Milstein C: Continuous cultures of fused cells secreting antibody of predefined specificity.Nature (London) 256 494 (1975).CrossRefGoogle Scholar
  2. 2.
    Yang H M, Reisfeld R A: Doxorubicin conjugated with a monoclonal antibody directed to a human melanoma-associated proteoglycan suppresses the growth of established tumor xenografts in nude mice.Proc natn Acad Sci USA 85, l189 (1988).CrossRefGoogle Scholar
  3. 3.
    Gilliland D G, Steplewski Z, Collier R J, Mitchell K F, Chang T H, Koprowski H: Antibody-directed cytotoxic agents: use of monoclonal antibody to direct the action of toxin A chains to colorectal carcinoma cells.Proc natn Acad Sci USA 77, 4539 (1980).CrossRefGoogle Scholar
  4. 4.
    Moldofsky P J, Sears H F, Mulhern C B, Hammond N D, Powe J, Gatenby R A, Steplewski Z, Koprowski H: Detection of metastatic tumor in normal-sized retroperitoneal lymph nodes by monoclonal antibody imaging.N Engl J Med 311, 106 (1985).Google Scholar
  5. 5.
    Chatal J-F, Saccavini J-C, Fumoleau P, Doulliard J-Y, Curtet C, Kremer M, LeMevel B, Koprowski H: Immunoscintigraphy of colon carcinoma.J Nucl Med 25, 307 (1984).PubMedGoogle Scholar
  6. 6.
    Mach J-P, Buchegger F, Forni M, Ritschard J, Berche L, Lumbroso J D, Schreyer M, Girardet C, Acolla R S, Carrel S: Use of radiolabeled monoclonal anti CEA antibodies for the detection of human carcinoma by external photoscanning and tomoscintigraphy.Immunol Today 2, 239 (1981).CrossRefGoogle Scholar
  7. 7.
    Colcher D, Esteban J M, Carrasquillo J A, Sugar-baker P, Reynolds J C, Bryant G, Larson S M, Schlom J: Quantitative analyses of selective radio- labeled monoclonal antibody localization in metastatic lesions of colorectal cancer patients.Cancer Res 47, 1185 (1987).PubMedGoogle Scholar
  8. 8.
    Colcher D, Carrasquillo J A, Esteban J M, Sugar-baker P, Reynolds J C, Siler K, Bryant G, Larson S M, Schlom J: Radiolabeled monoclonal antibody B72.3 localization in metastatic lesions of colorectal cancer patients.Nucl Med Biol 14, 251 (1987).Google Scholar
  9. 9.
    Esteban J M, Colcher D, Sugarbaker P, Carrasquillo J A, Bryant G, Thor A, Reynolds J C, Larson S M, Schlom J: Quantitative and qualitative aspects of radiolocalization in colon cancer patients of intravenously administered MAb B72.3.Int J Cancer 39, 50 (1987).CrossRefPubMedGoogle Scholar
  10. 10.
    Colcher D, Estaban J, Carrasquillo J A, Sugarbaker P, Reynolds J C, Bryant G, Larson S M, Schlom J: Complementation of intracavitary and intravenous administration of a monoclonal antibody (B72.3) in patients with carcinoma.Cancer Res 47, 4218 (1987).PubMedGoogle Scholar
  11. 11.
    Schlom J, Colcher D, Roselli M, Carrasquillo J A, Reynolds J C, Larson S M, Sugarbaker P, Tuttle S E, Martin E W: Tumor targeting with monoclonal antibody B72.3.Nucl Med Biol 16, 137 (1989).Google Scholar
  12. 12.
    Maguire R T, Schmelter R F, Pascucci V L, Conklin J J: Immunoscintigraphy of colorectal adenocarcinoma: results with site-specifically radiolabeled B72.3 (lllIn-CYT-103).Antibody, Immunoconjugates, and Radiopharmaceuticals 2, 257 (1989).Google Scholar
  13. 13.
    Renda A, Salvatore M, Sava M, Landi R, Lastoria S, Coppola L, Schlom J, Colcher D, Zannini G: Immunoscintigraphy in the follow-up of patients operated on for carcinoma of the sigmoid and rectum. Preliminary report with a new monoclonal antibody B72.3.Dis Colon and Rectum 30, 683 (1987).CrossRefGoogle Scholar
  14. 14.
    Carrasquillo J A, Sugarbaker P, Colcher D, Reynolds J C, Esteban J, Bryant G, Keenan A M, Perentesis P, Yokoyama K, Simpson D E, Ferroni P, Farkas R, Schlom J, Larson S M: Radioimmunoscintigraphy of colon cancer with I-131-labeled B72.3 monoclonal antibody.J Nucl Med 29, 1022 (1988).PubMedGoogle Scholar
  15. 15.
    Yokoyama K, Carrasquillo J A, Chang A E, Colcher D, Roselli M, Sugarbaker P, Sindelar W, Reynolds J C, Perentesis P, Gansow O A, Francis B, Adams R, Finn R, Schlom J, Larson S M: Differences in biodistribution of indium-111- and iodine-131-labeled B72.3 monoclonal antibodies in patients with colorectal cancer.J Nucl Med 30, 320 (1989).PubMedGoogle Scholar
  16. 16.
    Horan Hand P, Nuti M, Colcher D, Schlom J: Definition of antigenic heterogeneity and modulation among human mammary carcinoma cell populations using monoclonal antibodies to tumor associated antigens.Cancer Res 43, 728 (1983).Google Scholar
  17. 17.
    Colcher D, Horan Hand P, Nuti M, Schlom J: A spectrum of monoclonal antibodies reactive with mammary tumor cells.Proc natn Acad Sci USA 78, 3199 (1981).CrossRefGoogle Scholar
  18. 18.
    Johnson V G, Schlom J, Paterson A J, Bennett J, Magnani J L, Colcher D: Analysis of a human tumor- associated glycoprotein (TAG-72) identified by monoclonal antibody B72.3.Cancer Res 46, 850 (1986).PubMedGoogle Scholar
  19. 19.
    Nuti M, Teramoto Y A, Mariani-Costantini R, Horan Hand P, Colcher D, Schlom J: A monoclonal antibody (B72.3) defines patterns of distribution of a novel tumor-associated antigen in human mammary carcinoma cell populations.Int J Cancer 29, 539 (1982).CrossRefPubMedGoogle Scholar
  20. 20.
    Stramignoni D, Bowen R, Atkinson B, Schlom J: Differential reactivity of monoclonal antibodies with human colon adenocarcinomas and adenomas.Int J Cancer 31, 543 (1983).CrossRefPubMedGoogle Scholar
  21. 21.
    Thor A, Ohuchi N, Szpak C A, Johnston W W, Schlom J: Distribution of oncofetal antigen tumor- associated glycoprotein-72 defined by monoclonal antibody B72.3.Cancer Res 46, 3118 (1986).PubMedGoogle Scholar
  22. 22.
    Thor A, Viglione M J, Muraro R, Ohuchi N, Schlom J, Gorstein F: Monoclonal antibody B72.3 reactivity with human endometrium: A study of normal and malignant tissues.Int J Gyn Path 6, 235 (1987).CrossRefGoogle Scholar
  23. 23.
    Wolf B C, D’Emilia J C, Salem R R, De Coste D, Sears H F, Gottlieb L S, Steele G D: Detection of the tumor-associated glycoprotein antigen (TAG-72) in premalignant lesions of the colon.J natn Cancer Inst 81, 1913 (1989).CrossRefGoogle Scholar
  24. 24.
    Muraro R, Kuroki M, Wunderlich D, Poole D J, Colcher D, Thor A, Greiner J W, Simpson J F, Molinolo A, Noguchi P, Schlom J: Generation and characterization of B72.3 second generation monoclonal antibodies reactive with the tumor associated glycoprotein 72 antigen.Cancer Res 48, 4588 (1988).PubMedGoogle Scholar
  25. 25.
    Gero E J, Colcher D, Ferroni P, Melsheimer R, Giani S, Schlom J, Kaplan P: The CA 72-4 radioimmunoassay for the detection of the TAG-72 carcinoma associated antigen in serum of patients.J din Lab Anal 3, 360 (1989).CrossRefGoogle Scholar
  26. 26.
    Guadagni F, Roselli M, Amato T, Cosimelli M, Mannella E, Perri P, Abbolito M R, Cavaliere R, Colcher D, Greiner J W, Schlom J: Tumor-associated glycoprotein-72 (TAG-72) serum levels complement carcinoembryonic antigen (CEA) levels in monitoring patients with gastrointestinal carcinoma: a longitudinal study. Cancer (1991) (in press).Google Scholar
  27. 27.
    Wanebo H J, Rao B, Pinsky C M, Hoffman R G, Stearns M, Schwartz M K, Oettger H F: Preoperative carcinoembryonic antigen levels as a prognostic indicator of colorectal cancer.N Engl J Med 299, 448 (1978).PubMedGoogle Scholar
  28. 28.
    Herlyn M, Sears H F, Steplewski Z, Koprowski H:Monoclonal antibody detection of a circulating tumor associated antigen. I. Presence of antigen in sera of patients with colorectal, gastric and pancreatic carcinoma.J clin Immunol 2, 135 (1982).CrossRefPubMedGoogle Scholar
  29. 29.
    Sears H F, Flerlyn M, Del Villano B, Steplewski Z, Koprowski H: Monoclonal antibody detection of a circulating tumor associated antigen. II. A longitudinal evaluation of patients with colorectal cancer.J clin Immunol 2, 141 (1982).CrossRefPubMedGoogle Scholar
  30. 30.
    Goldenberg D M, Neville A M, Cortes A C, Go V L W, Holyoke E D, Isselbacher K J, Schein P S, Schwartz M: Carcinoembryonic antigen: its role as a marker in the management of cancer: a National Institutes of Health Consensus Development Conference.Ann Intern Med 94, 407 (1987).Google Scholar
  31. 31.
    Sikorska H, Shuster J, Gold P: Clinical applications of carcinoembryonic antigen.Cancer Detect Prev 12, 321 (1988).PubMedGoogle Scholar
  32. 32.
    Wessels B W, Rogus R D: Radionuclide selection and model absorbed dose calculation for radiolabeled tumor associated antibodies.Med Phys 11, 638 (1984).CrossRefPubMedGoogle Scholar
  33. 33.
    Colcher D, Milenic D E, Ferroni P, Carrasquillo J A, Reynolds J C, Roselli M, Larson S M, Schlom J:In vivo fate of monoclonal antibody B72.3 in patients with colorectal cancer.J Nucl Med,1133 (1990).Google Scholar
  34. 34.
    Primus F J, Kelley E A, Hansen H J, Goldenberg D M: “Sandwich”-type immunoassay for carcinoembryonic antigen in patients receiving murine monoclonal antibodies for diagnosis and therapy.Clin Chem 34, 261 (1988).PubMedGoogle Scholar
  35. 35.
    Ferroni P, Milenic D, Roselli M, Carrasquillo J A, Raubitschek A, Schlom J, Colcher D: Potential for artifacts in monitoring for the detection of tumor associated antigens (TAG-72 and CEA) in serum from patients undergoing MAb-based diagnostic and therapeutic protocols.Int J Biol Markers 5, 166 (1990).PubMedGoogle Scholar
  36. 36.
    Martin D T, Hinkle G H, Tuttle S, Olsen J O, Nabi H, Houchens D, Thurston M, Martin E W: Intraoperative radioimmunodetection of colorectal tumor with a hand-held radiation detector.Am J Surg 150, 672 (1985).CrossRefPubMedGoogle Scholar
  37. 37.
    Nieroda C A, Mojzisik C Sardi A, Farrar W, Hinkle G, Siddiqi H, Ferrara P, James A, Schlom J. Thurston M, Martin E W: Staging of carcinoma of the breast using a hand-held gamma detecting probe and monoclonal antibody B72.3.Surg Gvnecol Obstet 169, 35 (1989).Google Scholar
  38. 38.
    Sickle-Santanello B J, O’Dwyer P J, Mojzisik C, Tuttle S E, Hinkle J H, Rousseau H, Schlom J, Colcher D, Thurston M O, Nieroda C, Sardi A, Farrar W B, Minton J P, Martin E W: Radioimmunoguided surgery using the monoclonal antibody B72.3 in colorectal tumors.Dis Colon Rectum 30, 761 (1987).CrossRefPubMedGoogle Scholar
  39. 39.
    Roselli M, Schlom J, Gansow O A, Raubitschek A, Mirzadeh S, Brechbiel M W, Colcher D: Comparative biodistributions of yttrium- and indium-labeled monoclonal antibody B72.3 in athymic mice bearing human colon carcinoma xenografts.J Nucl Med 30, 672 (1989).PubMedGoogle Scholar
  40. 40.
    Schlom J, Molinolo A, Simpson J F, Siler K, Roselli M, Hinkle G, Houchens D P, and Colcher D: Advantage of dose fractionation in monoclonal antibody-targeted radioimmunotherapy.J natn Cancer Inst 82, 763 (1990).CrossRefGoogle Scholar
  41. 41.
    Colcher D, Milenic D, Roselli M, Raubitschek A, Yarranton G, King D, Adair J, Whittle N, Bodmer M, Schlom J: Characterization and biodistribution of recombinant and recombinant/chimeric constructs of monoclonal antibody B72.3.Cancer Res 49, 1738 (1989).PubMedGoogle Scholar
  42. 42.
    Hutzell P, Kashmiri S, Colcher D, Primus J, Horan Hand P, Roselli M, Finch M, Yarranton G, Bodmer M, Whittle N, King D, Loullis C C, McCoy D W, Callahan R, Schlom J: Generation and characterization of a recombinant/chimeric B72.3 (human γ1).Cancer Res 51, 181 (1991).PubMedGoogle Scholar
  43. 43.
    Colcher D, Bird R, Roselli M, Hardman K D, Johnson S, Pope S, Dodd S W, Pantoliano M W, Milenic D E, Schlom J:In vivo tumor targeting of a recombinant single-chain antigen-binding protein.J natn Cancer Inst 82, 1191 (1990).CrossRefGoogle Scholar
  44. 44.
    Colcher D, Minelli M F, Roselli M, Muraro R, Simpson-Milenic D, Schlom J: Radioimmunolocalization of human carcinoma xenografts with B72.3 second-generation monoclonal antibodies.Cancer Res 48, 4597 (1988).PubMedGoogle Scholar
  45. 45.
    Greiner J W, Guadagni F, Noguchi P, Pestka S, Colcher D, Fisher P B, Schlom J: Recombinant interferon enhances monoclonal antibody-targeting of carcinoma lesionsin vivo. Science 235, 895 (1987).Google Scholar

Copyright information

© Humana Press Inc. 1991

Authors and Affiliations

  • Mario Roselli
    • 1
  • Carlo U. Casciani
    • 1
  • Fiorella Guadagni
    • 2
  • Oreste Buonomo
    • 1
  • Beniamino Iorio
    • 1
  • Alessandra Diodati
    • 1
  • Vincenzo Vittorini
    • 1
  • John W. Greiner
    • 3
  • David Colcher
    • 2
    • 3
  • Jeffrey Schlom
    • 3
  1. 1.Department of SurgeryII University of Rome, School of MedicineRomeItaly
  2. 2.Regina Elena Cancer InstituteRomeItaly
  3. 3.Laboratory of Tumor Immunology and BiologyNational Cancer InstituteBethesdaUSA

Personalised recommendations